Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders

Gabriela V. Obrocea, Robert M. Dunn, Mark A. Frye, Terence A. Ketter, David A. Luckenbaugh, Gabriele S. Leverich, Andrew M. Speer, Elizabeth A. Osuch, Kamal Jajodia, Robert M. Post

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


Background: The objective of the current study was to examine possible clinical predictors of positive response to lamotrigine or gabapentin monotherapy in treatment-refractory affectively ill patients. Methods: Forty-five patients with treatment refractory bipolar (n = 35) or unipolar (n = 10) affective disorder participated in a clinical study evaluating six weeks of treatment with lamotrigine, gabapentin, or placebo monotherapy given in a double-blind, randomized fashion with two subsequent cross-overs to the other agents. Patients received daily mood ratings and weekly cross-sectional scales. Much or very much improved on the Clinical Global Impression scale modified for bipolar illness was considered a positive response. Degree of response was correlated with a number of baseline demographic and course of illness variables in a univariate analysis and then by linear regression. Results: Response rates to lamotrigine (51%) exceeded those to gabapentin (28%) and placebo (21%). A positive response to lamotrigine monotherapy was associated with a bipolar diagnosis; fewer hospitalizations; fewer prior medication trials; and male gender (of which the latter two variables survived logistic regression). For gabapentin, degree of response correlated with shorter duration of illness; younger age; and lower baseline weight (with the latter two surviving linear regression). Conclusions: In this highly treatment-refractory population, lamotrigine appeared most effective for male patients with fewer prior medication trials. Gabapentin monotherapy, although not better than placebo, appeared most effective in those with younger age and lower baseline weight. These preliminary data in a treatment refractory subgroup may help in the further definition of the range of clinical utility of these widely used anticonvulsants.

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalBiological psychiatry
Issue number3
StatePublished - Feb 1 2002


  • Affective disorders
  • Anticonvulsants
  • Gabapentin
  • Lamotrigine
  • Monotherapy
  • Predictors

ASJC Scopus subject areas

  • Biological Psychiatry


Dive into the research topics of 'Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders'. Together they form a unique fingerprint.

Cite this